Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$510M |
| 2 |
Pfizer
PFE
|
+$265M |
| 3 |
Gilead Sciences
GILD
|
+$212M |
| 4 |
Comcast
CMCSA
|
+$191M |
| 5 |
Meta Platforms (Facebook)
META
|
+$184M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$369M |
| 2 |
SIAL
SIGMA - ALDRICH CORP
SIAL
|
+$330M |
| 3 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$230M |
| 4 |
Amgen
AMGN
|
+$223M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$145M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.46% |
| 2 | Healthcare | 12.72% |
| 3 | Financials | 10.51% |
| 4 | Industrials | 9.69% |
| 5 | Consumer Staples | 9.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Lightpath Technologies
LPTH
$648M
| $367K | ﹤0.01% |
+129,700
| New | +$228K |
|
2827
Champion Homes
SKY
$4.41B
| $367K | ﹤0.01% |
103,100
+8,700
| +9% | +$28K |
|
2828
Stratus Properties
STRS
$155M
| $367K | ﹤0.01% |
18,000
+2,100
| +13% | +$35.1K |
|
|
FCRE
2829
DELISTED
FC Global Realty Incorporated Common Stock
FCRE
| $366K | ﹤0.01% |
162,760
+14,740
| +10% | +$32.9K |
|
2830
ImmuCell
ICCC
$100M
| $360K | ﹤0.01% |
47,800
+2,600
| +6% | +$18.3K |
|
|
GLF
2831
DELISTED
GulfMark Offshore, Inc. Common Stock
GLF
| $360K | ﹤0.01% |
77,112
-289,200
| -79% | -$1.77M |
|
2832
EVI Industries
EVI
$188M
| $359K | ﹤0.01% |
86,200
+1,400
| +2% | +$5.34K |
|
|
CCXI
2833
DELISTED
ChemoCentryx, Inc.
CCXI
| $359K | ﹤0.01% |
44,300
+19,600
| +79% | +$139K |
|
2834
MediWound
MDWD
$181M
| $356K | ﹤0.01% |
5,957
+2,271
| +62% | +$143K |
|
|
SUMR
2835
DELISTED
Summer Infant, Inc.
SUMR
| $356K | ﹤0.01% |
17,756
-852
| -5% | -$14.6K |
|
2836
Upland Software
UPLD
$13.6M
| $355K | ﹤0.01% |
5,039
+1,999
| +66% | +$151K |
|
|
ADAP
2837
DELISTED
Adaptimmune Therapeutics
ADAP
| $353K | ﹤0.01% |
+29,300
| New | +$287K |
|
|
PACD
2838
DELISTED
Pacific Drilling S A
PACD
| $353K | ﹤0.01% |
42,040
-2,480
| -6% | -$32.8K |
|
|
GZT
2839
DELISTED
Gazit-globe Ltd
GZT
| $352K | ﹤0.01% |
39,200
+2,200
| +6% | +$22.3K |
|
2840
RAVE Restaurant Group
RAVE
$44.1M
| $351K | ﹤0.01% |
54,900
-10,400
| -16% | -$74K |
|
2841
First US Bancshares
FUSB
$93.7M
| $350K | ﹤0.01% |
39,200
+5,200
| +15% | +$43.3K |
|
2842
Mind CTI
MNDO
$20.6M
| $350K | ﹤0.01% |
138,375
-17,025
| -11% | -$45.1K |
|
|
WIRE
2843
DELISTED
Encore Wire Corp
WIRE
| $350K | ﹤0.01% |
+9,437
| New | +$382K |
|
|
HSNI
2844
DELISTED
HSN, Inc.
HSNI
| $350K | ﹤0.01% |
6,900
-29,500
| -81% | -$1.61M |
|
2845
MediciNova
MNOV
$66M
| $349K | ﹤0.01% |
98,200
-4,900
| -5% | -$15.6K |
|
|
CBIO
2846
Crescent Biopharma
CBIO
$555M
| $348K | ﹤0.01% |
609
+131
| +27% | +$86.8K |
|
|
BCRH
2847
DELISTED
BLUE CAPITAL REINSURANCE HOLDINGS LTD.
BCRH
| $348K | ﹤0.01% |
20,300
-1,700
| -8% | -$29.6K |
|
|
GFED
2848
DELISTED
Guaranty Federal Bancshares In
GFED
| $346K | ﹤0.01% |
22,700
+2,900
| +15% | +$42.8K |
|
|
TRT
2849
Trio-Tech International
TRT
$99.8M
| $345K | ﹤0.01% |
247,400
+2,200
| +0.9% | +$3.01K |
|
|
TBRA
2850
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $345K | ﹤0.01% |
34,365
-2,700
| -7% | -$28K |
|
Similar funds
Renaissance Technologies's Q4 2015 Portfolio in Review
As of Q4 2015, Renaissance Technologies held 3,639 positions worth $45.9B, up 9.5% from $41.9B the previous quarter. Its ten largest holdings account for 9.3% of the portfolio.
Renaissance Technologies deployed $3.07B of net new capital in Q4 2015, opening 509 new positions and adding to 1,872 existing holdings. Its largest new stake was Apple: 17,852,932 shares worth $470M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 11% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $369M trimmed.
- Renaissance Technologies's largest Q4 2015 buy was Apple: 17,852,932 shares worth $470M.
- Renaissance Technologies added most to Gilead Sciences in Q4 2015, an estimated $212M increase.
- Renaissance Technologies's biggest Q4 2015 reduction was Alphabet (Google) Class C, cutting an estimated $369M.
- Renaissance Technologies fully exited SIGMA - ALDRICH CORP in Q4 2015, selling an estimated $330M.
- Renaissance Technologies's ten largest holdings make up 9.3% of its $45.9B portfolio in Q4 2015.
- Renaissance Technologies opened 509 new positions and closed 386 in Q4 2015.
- Renaissance Technologies's portfolio value rose 9.5% quarter-over-quarter to $45.9B.
Based on Renaissance Technologies's 13F filing for Q4 2015, filed 11 Feb 2016.